Table 2.
Patients who discontinued DTG/ABC/3TC.
| Prior regimena | Reason for switch to DTG/ABC/3TC | Days on DTG/ABC/3TC | Reason for DTG/ABC/3TC discontinuationb | Event | Subsequent regimen | Returned to prior regimen | AE ceased | Regained/ maintained viral suppression |
|---|---|---|---|---|---|---|---|---|
| DTG + ABC/3TC | Simplification | 175 | Toxicity/intolerance | Headachec | DTG + ABC/3TC | Yes | Yes | Yes |
| ATV/r + ABC/3TC | Simplification | 75 | Blip | Single event of 63 copies/ml | ATV/r + ABC/3TC | Yes | Yes | |
| DTG + ABC/3TC | Simplification | 381 | Toxicity/intolerance | Creatinine | EVG/c/TDF/FTC | No | No | Yes |
| ATV/r + TDF/FTC | Simplification | 82 | Toxicity/intolerance | Abdominal discomfort | ATV/r + TDF/FTC | Yes | Yes | Yes |
| RAL + ABC/3TC | Simplification | 126 | Toxicity/intolerance | Insomnia | RAL + ABC/3TC | Yes | Yes | Yes |
| NVP + TDF/FTCd | Toxicity/intolerance | 75 | Toxicity/intolerance | Anxietye | NVP + TDF/FTC | Yes | Yes | Yes |
| RAL + ABC/3TCd | Toxicity/intolerance | 169 | Toxicity/intolerance | Dry mouth | RAL + ABC/3TC | Yes | Yes | Yes |
| RAL + TDF/FTC | Simplification | 27 | Toxicity/intolerance | Rash | RAL + TDF/FTC | Yes | Yes | Yes |
| DTG + ABC/3TC | Simplification | 43 | Drug–drug interactions | Cigarettes and risk of CVD | ATV/r + TDF/FTC | No | Yes | |
| DTG + ABC/3TCf | Patient preference | 304 | Toxicity/intolerance | Malaiseg | NVP + ABC/3TC | No | Yes | Yes |
| NVP + ABC/3TC | Simplification | 199 | Patient preference | NVP + ABC/3TC | Yes | Yes | ||
| DTG + ABC/3TC | Simplification | 345 | Toxicity/intolerance | Anxiety | DRV/r + ABC/3TC | No | Yes | Yes |
| RAL + DRV/r + ABC/3TC | Simplification | 186 | Toxicity/intolerance | Rhabdomyolysish | RPV/TDF/FTC | No | Yes | Yes |
| RAL + NVP + 3TC | Simplification | 21 | Toxicity/intolerance | Nausea | RAL + NVP + 3TC | Yes | Yes | Yes |
3TC: lamivudine; ABC: abacavir; AE: adverse event; ATV/r: atazanavir/ritonavir; c: cobicistat; CVD: cardiovascular disease; DRV/r: darunavir/ritonavir; DTG: dolutegravir; EVG: elvitegravir; NVP: nevirapine; RAL: raltegravir; RPV: rilpivirine; TDF/FTC: tenofovir/emtricitabine.
aSwitched from prior regimens for simplification, with three exceptions.
bMedian time on DTG/ABC/3TC treatment was 147.5 (IQR 75–195.75) days in these patients.
cThis subject was entered two days after study closure.
dDiscontinued prior regimen due to a pre-existing toxicity/intolerance.
eHistory of anxiety.
fDiscontinued prior regimen due to patient preference.
gAches, shortness of breath, tight chest, coughing, fatigue.
hSerious AE: onset bilateral arms, required hospitalisation.